The CD133 protein has been considered a key biomarker of cancer stem cells in various cancers. However, the expression status and prognostic significance of CD133 in cutaneous squamous cell carcinoma (cSCC) are poorly understood.
However, 8% of invasive cSCCs recur, and 5% metastasize within 5 years. 3 Therefore, recent cSCC studies 10, 11 have focused on the discovery of specific molecular biomarkers that could serve as reliable prognostic indicators, but novel biomarkers to predict outcomes in patients with cSCC remain limited. Cancer stem cells (CSCs) are a small population of tumor cells and are the only cells that possess the ability to initiate and maintain tumor growth. 12, 13 Recently, CSCs have been identified and isolated from several human solid cancers and were suggested to be a source of cancer cells responsible for the initial disease, progression, metastasis, recurrence, and resistance to therapy. 14 There are various stem cell biomarkers of different cellular origins for CSCs. The CD133 protein, also known as human prominin 1, is a transmembrane glycoprotein that has been considered a putative and important CSC biomarker in various tumors, including melanoma and lung, breast, colon, and brain cancer. [15] [16] [17] [18] [19] [20] Moreover, high CD133 expression was correlated with poor clinical outcomes in some cancers.
21-24
A few studies 20, 25, 26 have investigated CD133 expression in skin cancers, including melanoma, but, to our knowledge, there has been little consideration of CD133 expression in cSCC tissue. In this study, a tissue microarray was used to examine the distribution and frequency of CD133 expression in cSCC tissue and in adjacent nonmalignant epithelial tissue by immunohistochemistry (IHC). Receiver operating characteristic (ROC) curve analysis was applied to define a cutoff value for high CD133 expression. In addition, clinicopathological and prognostic significance of CD133 expression in cSCC tissue was analyzed.
Methods

Patients and Tissue Samples
For this study, paraffin-embedded clinicopathological samples were obtained from the archives of the First Affiliated Hospital, Sun Yat-Sen University Cancer Center, and Guangzhou Institute of Dermatology and Venerology, between June 1, 1996, and December 31, 2010. In total, 165 patients with cutaneous SCC were included in the study who met the following criteria: (1) the diagnosis was confirmed by a dermatopathologist (M.-Y.C. or R.-Z.L.), (2) they had a primary tumor without any preoperative anticancer treatment, and (3) a resected tissue specimen and follow-up data were available. These cSCCs occurred in areas of sun exposure, including the head, face, and neck. 
Immunohistochemistry
Tissue microarray slides were dried overnight at 37°C, deparaffinized in xylene, rehydrated through graded alcohol, immersed in 3% hydrogen peroxide for 20 minutes to block endogenous peroxidase activity, and antigen retrieved by pressure cooking for 3 minutes in EDTA buffer (pH 8.0). The slides were then preincubated with 10% normal goat serum at room temperature for 30 minutes to reduce nonspecific reactions. Next, the slides were incubated with mouse monoclonal anti-CD133 (human prominin 1; EMD Millipore) at a concentration of 3 ng/mL for 2 hours at room temperature. Then, the slides were incubated with a secondary antibody (Envision; Dako) for 1 hour at room temperature and stained with 3,30-diaminobenzidine. Finally, the sections were counterstained with Mayer hematoxylin, dehydrated, and mounted. A negative control was obtained by replacing the primary antibody with normal mouse IgG. Known immunostaining-positive slides (of hepatocellular carcinoma tissue) were used as positive controls.
IHC Evaluation
Immunohistochemistry was performed as described previously. 30 The CD133 
Selection of the Cutoff Value for High CD133 Expression
A ROC curve analysis was used to establish a cutoff value for high CD133 expression in tumors using the shortest distance from the curve to the point with the maximum sensitivity and specificity (0.0, 1.0). 31 For CD133, the sensitivity and specificity were plotted for each outcome under examination, generating various ROC curves ( Figure 1 ). Tumors at or below the cutoff value were designated as having low CD133 expression, and tumors above the cutoff value were designated as having high CD133 expression. Using ROC curve analysis, we dichotomized the following clinicopathological data: tumor size (≤5 or >5 cm), tumor grade (well to moderately or poorly differentiated), pT classification (T1-T2 or T3-T4), pN classification (N0 or N1), tumor stage (I-II or III-IV), and survival status (death from cSCC or censored).
Statistical Analysis
Statistical analyses were performed using a software package (SPSS, version 13.0; IBM). An ROC curve analysis was used to determine the cutoff value for high CD133 expression. Correlation of CD133 expression with clinicopathological features of patients with cSCC was evaluated by the χ 2 test. Univariable and multivariable survival analyses were performed using a Cox proportional hazards regression model. Survival curves were plotted by the Kaplan-Meier method. Two-tailed P < .05 was considered statistically significant.
Results
CD133 Expression in cSCC Tissue and Adjacent Nonmalignant Epithelial Tissue
The CD133 expression was evaluated in 165 cSCC samples, and immunoreactivity of CD133 in cSCC tissue ranged from 0% to 100%. The CD133 IHC staining in cSCC tissue and adjacent nonmalignant epithelial tissue showed mixed membranous and cytoplasmic staining in tumor cells ( Figure 2 
Selection of a Cutoff Value for High CD133 Expression
The ROC curves for each clinicopathological parameter (Figure 1) show the point on the curve closest to the point that expression was defined as greater than 65% of tumor cells with positive CD133 staining. High CD133 expression was associated with poorly differentiated and advanced-stage cSCC and with poor survival (Figure 1 ).
Association of CD133 Expression With Clinicopathological Features of cSCC
High CD133 expression was greater in patients with poorly differentiated cSCC (P = .01) and with advanced tumor stage (P = .02) ( Table 1 ). There was no significant correlation between CD133 expression and the other clinicopathological parameters, including patient age, sex, tumor location and size, and pT and pN classification (P > .05 for all).
Association of Clinicopathological Features With CD133 Expression and Survival of Patients With cSCC in the Univariable Survival Analysis
To confirm the representativeness of the cSCC samples in our study, the sample was analyzed according to established prognostic factors for patient survival. The Kaplan-Meier analysis demonstrated a significant effect of several well-known clinicopathological prognostic factors, including tumor size (P = .03), pN classification (P = .009), and tumor stage (P = .003), on overall patient survival ( Table 2) . Moreover, an assessment of recurrence-free survival ( Figure 3A ) and overall survival ( Figure 3B ) (P < .001 for both) showed that high CD133 expression was correlated with poor survival in patients with cSCC.
Independent Prognostic Factors for cSCC in the Multivariable Cox Proportional Hazards Regression Model
Several features of cSCC observed to be prognostic factors by univariable analysis, including CD133 expression and clinicopathological variables that were significant by univariable analysis (ie, tumor size, pN classification, and tumor stage), were further evaluated by multivariable analysis. A multivariable regression analysis based on the Cox proportional hazards regression model was applied to test the independent value of each parameter in predicting overall survival. The results showed that high CD133 expression was an independent prognostic factor for poor overall survival (hazard ratio, 1.915; 95% CI, 1.195-3.349; P = .02) ( Table 2 ). Tumor stage was found to be another independent prognostic factor for poor overall survival (hazard ratio, 1.812; 95% CI, 1.012-3.246) (P = .045). The sensitivity and 1−specificity for each outcome are plotted. AUC indicates area under the curve.
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Cancer Stem Cell Biomarker CD133 in Cutaneous Squamous Cell Carcinoma sion was observed in many cSCC samples, and it was more frequently observed in cSCC tissue than in adjacent nonmalignant epithelial tissue. High CD133 expression was positively correlated with poorly differentiated cSCC and with advanced tumor stage. In addition, high CD133 expression and other clinicopathological prognostic factors (eg, tumor stage) were strong and independent predictors of poor overall survival by univariable and multivariable analyses. Previous evidence has suggested that a CD133-positive subpopulation of multipotent cells has biological features of CSCs and can be used to identify putative CSCs of solid tumors.
35 High CD133 expression levels were associated with poor prognosis in solid tumors, including lung, breast, colon, and brain cancers. [15] [16] [17] [18] [19] Recent data document CD133 expression in skin tumors, including staining patterns in melanoma and cSCC. 26 Our results showed that high CD133 expression was observed in many of our cSCC samples and was associated with poorly differentiated tumor and with advanced tumor stage. It was previously reported that tumor-initiating cells are present in human cSCC, are enriched in the CD133-positive cSCC subpopulation, and exhibit the stem cell property of self-renewal. 36 These findings provided evidence that CSCs or CD133 upregulation may have an important role in the tumorigenic process and development of cSCC. Keratinocytes with dysfunctional p53 as a result of irradiation cannot undergo apoptosis but demonstrate clonal expansion, which is manifested clinically as the development of actinic keratosis and SCC in situ. 3 Although the mechanism of CD133 and CSCs in the tumorigenesis and progression of cSCC has not been identified, studies 37, 38 have indicated that the CD133-positive cell population demonstrates significant resistance to transforming growth factor β-induced apoptosis and tumor necrosis factor-related apoptosis-inducing ligandinduced apoptosis compared with CD133-negative cells. Moreover, silencing of CD133 can impair the self-renewal and tumorigenic capacity of tumor cells. 39 The results of these studies suggested that uncontrolled proliferation of CSCs (CD133 cells) may lead to SCC in situ and invasive cSCC. Furthermore, the findings herein suggested that CD133 expression in cSCC tissue may facilitate an increase in malignant clinical features or lead to a worse prognosis. Therefore, IHC investigation of CD133 expression may be a good tool to identify patients with higher risk of worse cSCC progression. New treatment strategies for patients with poorly differentiated cSCC may be developed that target tumors containing a higher frequency of CD133 (a CSC biomarker). 39, 40 A few limitations are inherent to the present study. First, our study was retrospective and included a single biomarker (CD133). Second, the study enrolled few patients and lacked standardization with respect to the follow-up period. Third, although correlation of CD133 expression in SCC tissue with patient survival was the focus of our study, the underlying mechanism by which CD133 affects prognosis in patients with cSCC remains elusive and will require future investigation. The numbers at risk are 81 with low expression and 84 with high expression. A, Total probability of recurrence-free survival is shown. B, Total probability of overall survival is shown. 
